Mouse models for studies of cardiovascular complications of type 1 diabetes

Annals of the New York Academy of Sciences

Volumn 1103, Issue , 2007, Pages 202-217

  Shen, Xia ^a   Bornfeldt, Karin E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Cardiomyopathy; Diabetes; Mouse models

Indexed keywords

APOLIPOPROTEIN E; CALMODULIN; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; STREPTOZOCIN;

ATHEROSCLEROSIS; BAGG ALBINO MOUSE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HEART VENTRICLE FUNCTION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; VIRUS INFECTION;

MUS; MUS MUSCULUS;

EID: 34249033992     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1394.004     Document Type: Review

References (72)

1. LAING, S.P., A.J. SWERDLOW, S.D. SLATER, et al. 2003. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46: 760-765.
2. MOSS, S.E., R. KLEIN & B.E. 1991. Cause-specific mortality in a population-based study of diabetes. Am. J. Public Health 81: 1158-1162.
3. RUDERMAN, N.B. & C. HAUDENSCHILD. 1984. Diabetes as an atherogenic factor. Prog. Cardiovasc. Dis. 26: 373-412.
4. ANDRESEN, J.L., L.M. RASMUSSEN & T. LEDET. 1996. Diabetic macroangiopathy and atherosclerosis. Diabetes 45(Suppl 3): S91-S94.
5. BORCH-JOHNSEN, K. & S. KREINER. 1987. Proteinuria: value as predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. BMJ 294: 1561-1564.
6. NATHAN, D.M., P.A. CLEARY, J.Y. BACKLUND, et al. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353: 2643-2653.
7. STEHOUWER, C.D. 2004. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol. Dial. Transplant. 19: 778-781.
8. LANDSBERG, L. & M. MOLITCH. 2004. Diabetes and hypertension: pathogenesis, prevention and treatment. Clin. Exp. Hypertens. 26: 621-628.
9. YKI-JÄRVINEN H. 2001. Management of type 2 diabetes mellitus and cardiovascular risk. Drugs 60: 975-983.
10. GINSBERG, H.N. 1991. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 14: 839-855.
11. DCCT; THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. 1993. The effects of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986.
12. NATHAN, D.M., J. LACHIN, P. CLEARY, et al. 2003. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 348: 2294-2303.
13. MCGILL, H.C. JR., C.A. MCM AHAN, A.W. ZIESKE, et al. 2001. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 103: 1546-1550.
14. MCGILL, H.C. JR., C.A. MCM AHAN, G.T. MALCOM, et al. 1995. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler. Thromb. Vasc. Biol. 15: 431-440.
15. JÄRVISALO, M.J., A. PUTTO-LAURILA, L. JARTTI, et al. 2002. Carotid artery intimamedia thickness in children with type 1 diabetes. Diabetes 51: 493-498.
16. GOTZSCHE, O., A. DARWISH, L. GOTZSCHE, et al. 1996. Incipient cardiomyopathy in young insulin-dependent diabetic patients: a seven-year prospective Doppler echocardiographic study. Diabet. Med. 13: 834-840.
17. FRANCIS, G.S. 2001. Diabetic cardiomyopathy: fact or fiction? Heart 85: 247-248.
18. AN, D. & B. RODRIGUES. 2006. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am. J. Physiol. Heart. Circ. Physiol. 291: H1489-H1506.
19. KUNJATHOOR, V.V., D.L. WILSON & R.C. LEBOEUF. 1996. Increased atherosclerosis in streptozotocin-induced diabetic mice. J. Clin. Invest. 97: 1767-1773.
20. SCHNEDL, W.J., S. FERBER, J.H. JOHNSON, et al. 1994. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43: 1326-1333.
21. WANG, Z. & H. GLEICHMANN. 1998. GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47: 50-56.
22. MACDOUGALL, E.D., F. KRAMER, P. POLINSKY, et al. 2006. Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. Am. J. Pathol. 168: 2064-2073.
23. 0) mice. Acta Histochem. 108: 415-424.
24. GOUGH, P.J., I.G. GOMEZ, P.T. WILLE, et al. 2006. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116: 59-69.
25. DE NOOIJER, R., C.J. VERKLEIJ, J.H. VONDER THUSEN, et al. 2006. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler. Thromb. Vasc. Biol. 26: 340-346.
26. ROSENFELD, M.E., P. POLINSKY, R. VIRMANI, et al. 2000. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 20: 2587-2592.
27. GOLDBERG, I.J. & H.M. DANSKY. 2006. Diabetic vascular disease: an experimental objective. Arterioscler. Thromb. Vasc. Biol. 26: 1693-1701.
28. TSE, J., B. MARTIN-MCNAULTY, M. HALKS-MILLER, et al. 1999. Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 β-estradiol. Atherosclerosis 144: 303-313.
29. HAYEK, T., K. HUSSEIN, M. AVIRAM, et al. 2005. Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis 183: 25-33.
30. VIKRAMADITHYAN, R.K., Y. HU, H.L. NOH, et al. 2005. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 115: 2434-2443.
31. RENARD, C.B., F. KRAMER, F. JOHANSSON, et al. 2004. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 114: 659-668.
32. REAVEN, P., S. MERAT, F. CASANADA, et al. 1997. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 17: 2250-2256.
33. KANTER, J.E., F. JOHANSSON & K.E. BORNFELDT. 2007. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ. Res. In press.
34. VON HERRATH, M.G. & M.B. OLDSTONE. 1997. Interferon-γ is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185: 531-539.
35. LAMHARZI, N., C.B. RENARD, F. KRAMER, et al. 2004. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 53: 3217-3225.
36. GERRITY, R.G., R. NATARAJAN, J.L. NADLER, et al. 2001. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50: 1654-1665.
37. SRIVASTAVA, S.K., K.V. RAMANA & A. BHATNAGAR. 2005. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26: 380-392.
38. BUCCIARELLI, L.G., T. WENDT, W. QU, et al. 2002. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835.
39. PARK, L., K.G. RAMAN, K.J. LEE, et al. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4: 1025-1031.
40. GOLDIN, A., J.A. BECKMAN, A.M. SCHMIDT, et al. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605.
41. BURKE, A.P., F.D. KOLODGIE, A. ZIESKE, et al. 2004. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol. 24: 1266-1271.
42. CULLEN, P., R. BAETTA, S. BELLOSTA, et al. 2003. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler. Thromb. Vasc. Biol. 23: 535-542.
43. PETERS, L.L., E.M. CHEEVER, H.R. ELLIS, et al. 2002. Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice. Physiol. Genomics 11: 185-193.
44. HOOVER-PLOW, J., A. SHCHURIN, E. HART, et al. 2006. Genetic background determines response to hemostasis and thrombosis. BMC Blood Disord. 6: 6.
45. WILLIAMS, H., J.L. JOHNSON, K.G. CARSON, et al. 2002. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 22: 788-792.
46. HU, W., P. POLINSKY, E. SADOUN, et al. 2005. Atherosclerotic lesions in the common coronary arteries of ApoE knockout mice. Cardiovasc. Pathol. 14: 120-125.
47. MACKMAN, N. 2005. Tissue-specific hemostasis in mice. Arterioscler. Thromb. Vasc. Biol. 25: 2273-2281.
48. CUI, J., D.T. EITZMAN, R.J. WESTRICK, et al. 2000. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 96: 4222-4226.
49. EITZMAN, D.T., R.J. WESTRICK, Y. SHEN, et al. 2005. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 111: 1822-1825.
50. ISERMANN, B., S.B. HENDRICKSON, M. ZOGG, et al. 2001. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J. Clin. Invest. 108: 537-546.
51. MATSUSAKA, H., S. KINUGAWA, T. IDE, et al. 2006. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. J. Cardiovasc. Pharmacol. 48: 95-102.
52. SHIOMI, T., H. TSUTSUI, M. IKEUCHI, et al. 2003. Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J. Am. Coll. Cardiol. 42: 165-172.
53. SEVERSON, D.L. 2004. Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes. Can. J. Physiol. Pharmacol. 82: 813-823.
54. FONAROW, G.C. & P. SRIKANTHAN. 2006. Diabetic cardiomyopathy. Endocrinol. Metab. Clin. North Am. 35: 575-599.
55. AN, D. & B. RODRIGUES. 2006. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 291: H1489-H1506.
56. NIELSEN, L.B., E.D. BARTELS & E. BOLLANO. 2002. Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. J. Biol. Chem. 277: 27014-27020.
57. KAJSTURA, J., F. FIORDALISO, A.M. ANDREOLI, et al. 2001. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50: 1414-1424.
58. MATSUSHIMA, S., S. KINUGAWA, T. IDE, et al. 2006. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 291: H2237-H2245.
59. SUBRAMANIAN, V., P. KRISHNAMURPTHY, K. SINGH, et al. 2007. Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 292: H673-H683.
60. WOLD, L.E., A.F. CEYLAN-ISIK, C.X. FANG, et al. 2006. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-ribose) polymerase and myosin heavy chain isozyme. Free Radic. Biol. Med. 40: 1419-1429.
61. 2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166-1171.
62. EPSTEIN, P.N., P.A. OVERBEEK & A.R. MEANS. 1989. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 58: 1067-1073.
63. LIANG, Q., E.C. CARLSON, R.V. DONTHI, et al. 2002. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51: 174-181.
64. SHEN, X., S. ZHENG, N.S. METREVELI, et al. 2006. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55: 798-805.
65. YE, G., N.S. METREVELI, R.V. DONTHI, et al. 2004. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53: 1336-1343.
66. KRALIK, P.M., G. YE, N.S. METREVELI, et al. 2005. Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. Cardiovasc. Toxicol. 5: 285-292.
67. BROWNLEE, M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
68. IWATA, K., T. NISHINAKA, K. MATSUNO, et al. 2006. Increased gene expression of glutathione peroxidase-3 in diabetic mouse heart. Biol. Pharm. Bull. 29: 1042-1045.
69. CAI, L., J. WANG, Y. LI, et al. 2005. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 54: 1829-1837.
70. UNGER, R.H. 2003. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab. 14: 398-403.
71. BORRADAILE, N.M. & J.E. SCHAFFER. 2005. Lipotoxicity in the heart. Curr. Hypertens. Rep. 7: 412-417.
72. CHIU, H.C., A. KOVACS, D.A. FORD, et al. 2001. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107: 813-822.